Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BGMNASDAQ:CMPSNASDAQ:ELVNNASDAQ:MLYS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBGMQilian International Holding Group$11.41-1.9%$10.13$5.26▼$14.78$1.11B1.5127,762 shs5,976 shsCMPSCOMPASS Pathways$3.09+3.7%$3.88$2.85▼$10.31$286.36M2.29759,176 shs680,937 shsELVNEnliven Therapeutics$21.51+4.5%$21.29$15.96▼$30.03$1.05B1.04270,689 shs198,600 shsMLYSMineralys Therapeutics$15.00-7.1%$11.27$8.24▼$18.38$941.78M1.5341,378 shs1.04 million shs2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBGMQilian International Holding Group+4.68%+14.81%+16.76%+32.91%+1,162,999,900.00%CMPSCOMPASS Pathways-2.93%-2.61%-19.46%-28.02%-67.99%ELVNEnliven Therapeutics-3.47%-1.48%-3.61%-9.38%+16.87%MLYSMineralys Therapeutics-3.75%-3.58%+74.59%+25.49%+25.78%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBGMQilian International Holding GroupN/AN/AN/AN/AN/AN/AN/AN/ACMPSCOMPASS Pathways2.7765 of 5 stars3.53.00.00.02.70.81.3ELVNEnliven Therapeutics2.8697 of 5 stars3.61.00.00.03.94.20.0MLYSMineralys Therapeutics3.2762 of 5 stars3.52.00.00.03.95.00.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBGMQilian International Holding Group 0.00N/AN/AN/ACMPSCOMPASS Pathways 3.00Buy$21.83606.58% UpsideELVNEnliven Therapeutics 3.20Buy$38.7580.15% UpsideMLYSMineralys Therapeutics 3.00Buy$27.0080.00% UpsideCurrent Analyst Ratings BreakdownLatest CMPS, ELVN, BGM, and MLYS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/21/2025ELVNEnliven TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$37.00 ➝ $39.003/10/2025MLYSMineralys TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.00 ➝ $30.003/4/2025CMPSCOMPASS PathwaysHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$45.00 ➝ $45.002/28/2025CMPSCOMPASS PathwaysCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$23.00 ➝ $15.002/27/2025CMPSCOMPASS PathwaysStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$11.002/24/2025MLYSMineralys TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy2/13/2025CMPSCOMPASS PathwaysHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$60.00 ➝ $45.002/13/2025MLYSMineralys TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$28.00 ➝ $24.002/13/2025MLYSMineralys TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.00 ➝ $30.001/15/2025CMPSCOMPASS PathwaysRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$18.00 ➝ $18.00(Data available from 3/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBGMQilian International Holding Group$25.10M44.20N/AN/A$6.10 per share1.87CMPSCOMPASS PathwaysN/AN/AN/AN/A$3.65 per shareN/AELVNEnliven TherapeuticsN/AN/AN/AN/A$5.97 per shareN/AMLYSMineralys TherapeuticsN/AN/AN/AN/A$3.84 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBGMQilian International Holding Group-$1.44MN/A0.00∞N/AN/AN/AN/AN/ACMPSCOMPASS Pathways-$118.46M-$2.30N/AN/AN/AN/A-63.85%-51.97%5/6/2025 (Estimated)ELVNEnliven Therapeutics-$71.58M-$1.89N/AN/AN/AN/A-29.46%-27.33%5/13/2025 (Estimated)MLYSMineralys Therapeutics-$177.81M-$3.64N/AN/AN/AN/A-67.97%-62.40%5/8/2025 (Estimated)Latest CMPS, ELVN, BGM, and MLYS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/13/2025Q4 2024ELVNEnliven Therapeutics-$0.53-$0.46+$0.07-$0.46N/A$0.03 million2/27/2025Q4 2024CMPSCOMPASS Pathways-$0.62-$0.63-$0.01-$0.63N/AN/A2/12/2025Q4 2024MLYSMineralys Therapeutics-$1.00-$0.98+$0.02-$0.98N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBGMQilian International Holding GroupN/AN/AN/AN/AN/ACMPSCOMPASS PathwaysN/AN/AN/AN/AN/AELVNEnliven TherapeuticsN/AN/AN/AN/AN/AMLYSMineralys TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBGMQilian International Holding GroupN/A3.392.82CMPSCOMPASS Pathways0.158.918.91ELVNEnliven TherapeuticsN/A17.4417.44MLYSMineralys TherapeuticsN/A14.0214.02Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBGMQilian International Holding GroupN/ACMPSCOMPASS Pathways46.19%ELVNEnliven Therapeutics95.08%MLYSMineralys Therapeutics84.46%Insider OwnershipCompanyInsider OwnershipBGMQilian International Holding Group58.66%CMPSCOMPASS Pathways4.25%ELVNEnliven Therapeutics29.20%MLYSMineralys Therapeutics33.24%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBGMQilian International Holding Group29897.22 million2.48 millionN/ACMPSCOMPASS Pathways12092.67 million65.51 millionOptionableELVNEnliven Therapeutics5049.00 million34.59 millionOptionableMLYSMineralys Therapeutics2862.79 million33.27 millionOptionableCMPS, ELVN, BGM, and MLYS HeadlinesRecent News About These CompaniesMineralys Therapeutics to Host Webinar on Lorundsrostat and Hypertension Treatment ProgressMarch 27 at 7:05 PM | msn.comMineralys Therapeutics to Host Conference Call on Advance-HTN and Launch-HTN Clinical Trial Results Featuring Dr. Luke LaffinMarch 27 at 9:03 AM | nasdaq.comProficio Capital Partners LLC Invests $285,000 in Mineralys Therapeutics, Inc. (NASDAQ:MLYS)March 27 at 3:17 AM | marketbeat.comMineralys Therapeutics (NASDAQ:MLYS) Shares Gap Up - Should You Buy?March 26 at 11:50 AM | marketbeat.comInsiders Make Huge Purchases of These 4 Biotech StocksMarch 26 at 8:40 AM | 247wallst.comMineralys Therapeutics (NASDAQ:MLYS) Shares Down 3.5% - Here's WhyMarch 25 at 4:41 PM | marketbeat.comMineralys Therapeutics, Inc. (MLYS): Among Stocks Receiving the Most Insider Love in MarchMarch 25 at 1:04 PM | insidermonkey.comMineralys Therapeutics to Host KOL Call to Discuss Clinical Data from Launch-HTN and Advance-HTN Pivotal Trials Tuesday, April 1, 2025, at 8:00 AM ETMarch 25 at 8:00 AM | globenewswire.comBuy Rating Justified for Mineralys Therapeutics, Inc. Due to Promising Study Results and Manageable Safety ProfileMarch 20, 2025 | tipranks.comMineralys Therapeutics (NASDAQ:MLYS) Stock Price Up 7.9% - Here's WhyMarch 20, 2025 | marketbeat.comMineralys Therapeutics (NASDAQ:MLYS) Hits New 12-Month High - Still a Buy?March 20, 2025 | marketbeat.comMineralys Therapeutics (NASDAQ:MLYS) Sees Strong Trading Volume Following Insider Buying ActivityMarch 20, 2025 | americanbankingnews.comMineralys Therapeutics to Present Phase 2 Trial Data on Lorundrostat for Uncontrolled Hypertension at ACC.25March 19, 2025 | nasdaq.comMineralys Therapeutics (NASDAQ:MLYS) Sees Strong Trading Volume on Insider Buying ActivityMarch 19, 2025 | marketbeat.comMineralys Therapeutics to Present Phase 2 Advance-HTN Trial Data at ACC.25March 19, 2025 | msn.comInsider Buying: Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Major Shareholder Purchases 600,000 Shares of StockMarch 18, 2025 | marketbeat.comInsider Buying: Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Director Buys 1,296,296 Shares of StockMarch 18, 2025 | marketbeat.comIs Mineralys Therapeutics, Inc. (MLYS) a Pump and Dump Stock Favored by Hedge Funds?March 18, 2025 | insidermonkey.comMineralys Therapeutics Announces Closing of Underwriters’ Option to Purchase Additional Shares in Connection with Public Offering of Common StockMarch 18, 2025 | markets.businessinsider.comMineralys Therapeutics Announces Closing of Underwriters' Option to Purchase Additional Shares in Connection with Public Offering of Common StockMarch 18, 2025 | globenewswire.comSamsara Biocapital Gp, Llc Acquires 600,000 Shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS) StockMarch 18, 2025 | insidertrades.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCMPS, ELVN, BGM, and MLYS Company DescriptionsQilian International Holding Group NASDAQ:BGM$11.46 -0.17 (-1.42%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Qilian International Holding Group Limited manufactures and distributes active pharmaceutical ingredients (APIs), traditional Chinese medicine derivatives (TCMD), and other by-products in China. The company provides licorice products, including Gan Di Xin, an antitussive and expectorant medicine; Qilian Shan Licorice Extract, an ingredient for pharmaceutical companies to manufacture traditional licorice tablets; and Qilian Shan licorice liquid extract, a primary ingredient for medical preparation companies to produce compound licorice oral solutions. It offers Qilian Shan oxytetracycline tablets to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and human; and Qilian Shan oxytetracycline APIs for pharmaceutical companies to manufacture medications. In addition, the company offers TCMD products, such as Ahan antibacterial paste to treat refractory chronic skin diseases; heparin products, including heparin sodium preparations for pharmaceutical companies to produce medications for cardiovascular diseases, cerebrovascular diseases, and hemodialysis; and Zhu Xiaochang sausage casings, which are natural food products for culinary application. Further, it provides Xiongguan organic fertilizers to improve crop yield and soil's chemical properties and reduce soil compaction; and Xiongguan organic-inorganic compound fertilizers to increased plant growth. Qilian International Holding Group Limited was incorporated in 2019 and is based in Jiuquan, the People's Republic of China.COMPASS Pathways NASDAQ:CMPS$3.09 +0.11 (+3.69%) Closing price 04:00 PM EasternExtended Trading$3.04 -0.04 (-1.46%) As of 07:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.Enliven Therapeutics NASDAQ:ELVN$21.51 +0.93 (+4.52%) Closing price 04:00 PM EasternExtended Trading$21.52 +0.00 (+0.02%) As of 04:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.Mineralys Therapeutics NASDAQ:MLYS$15.00 -1.15 (-7.12%) Closing price 04:00 PM EasternExtended Trading$14.75 -0.25 (-1.66%) As of 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Intuitive Machines Gains After Earnings Beat, NASA Missions Ahead Maybe It’s Time to Buy Some GameStop Stock Intel's Strategy to Win the Next AI Frontier Is Alphabet Too Cheap to Ignore After Its Recent Correction? Qualcomm Stock Is Coiling for a Breakout Tesla Stock: Has the Mother of All Comebacks Begun? Fortinet: A Top Cybersecurity Stock With Growth Catalysts Energy Transfer: Powering Data With Dividends and Diversification Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
